| |
Latest 10 SEC filings (by transaction date) for LFVN within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Performance Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -3,232 | |
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Performance Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -17,002 | |
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -15,107 | $6.39 |
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 3,232 | |
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 17,002 | |
Apr 3/24 | Apr 1/24 | Neufeld Alissa | Direct Ownership | Performance Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -2,668 | |
Apr 3/24 | Apr 1/24 | Neufeld Alissa | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -2,644 | $6.39 |
Apr 3/24 | Apr 1/24 | Neufeld Alissa | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 2,668 | |
Apr 3/24 | Apr 1/24 | Cunningham Kristen | Direct Ownership | Performance Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -3,001 | |
Apr 3/24 | Apr 1/24 | Cunningham Kristen | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -1,829 | $6.39 |
Sign up or login above to see all SEC filings within the past 6 months. |
Latest 10 SEC filings (by filing date) for LFVN within the last 6 months | [?] |
Amended Filing Footnote and/or Remark |
Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | Volume or Value | Price |
---|---|---|---|---|---|---|---|
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Performance Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -3,232 | |
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Performance Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -17,002 | |
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -15,107 | $6.39 |
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 3,232 | |
Apr 3/24 | Apr 1/24 | Fife Steven R | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 17,002 | |
Apr 3/24 | Apr 1/24 | Neufeld Alissa | Direct Ownership | Performance Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -2,668 | |
Apr 3/24 | Apr 1/24 | Neufeld Alissa | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -2,644 | $6.39 |
Apr 3/24 | Apr 1/24 | Neufeld Alissa | Direct Ownership | Common Stock | M - Exercise or conversion exempt under rule 16b-3 | 2,668 | |
Apr 3/24 | Apr 1/24 | Cunningham Kristen | Direct Ownership | Performance Restricted Stock Units | M - Exercise or conversion exempt under rule 16b-3 | -3,001 | |
Apr 3/24 | Apr 1/24 | Cunningham Kristen | Direct Ownership | Common Stock | F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3 | -1,829 | $6.39 |
Sign up or login above to see all SEC filings within the past 6 months. |
Sign up or login above to see the past 6 months of filings sorted by insider. . |
Competitors with Recent Insider Filings |
Eyepoint Pharmaceuticals (OQ:EYPT) |
AbbVie (N:ABBV) |
Merck & Co (N:MRK) |